Aurobindo launches custom R&D and manufacturing division
This article was originally published in Scrip
Aurobindo Pharma has launched a new unit, AuroSource, to handle its custom R&D and manufacturing services (CRAMS) business.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.